Week in Review

Collaborating for Continued Innovation

10.04.13 | By

The significant disease progress we've made reminds us to not only recognize and appreciate what we've already accomplished on behalf of patients, but also to look into the future and determine what more can be done.

We did just that in our “Conversations” forum this week. CEO John Castellani asked experts, On the one year anniversary of implementation of the Prescription Drug User Fee Act (PDUFA V), what element has shown the most promise? The responses we received highlighted PDUFA’s successes to date, noting the U.S. Food and Drug Administration (FDA) application review process for new medicines went from taking more than two years to decreasing by more than 60 percent. They also looked to the future and identified PDUFA’s most promising elements. Read exactly what health care experts said and join the discussion by visiting the “Conversations” webpage.

As we continue to look at the future of medicine and innovation, PhRMA is pleased to announce that on October 23, it will co-host “Alzheimer’s: The Puzzle, The Partners, The Path Forward,” with the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation. With the ultimate goal of finding treatments and preventative measures for this devastating disease, the forum will discuss how to accelerate the impact of pre-competitive collaborative efforts and explore the challenges in clinical trial recruitment unique to Alzheimer’s. If you are interested in participating in this event, you can register here.


More On PhRMA — powered by PhRMApedia


Cost in Context